global glp-1 obesity drug market size forecast 2030 How to Invest in Drugs: Stocks and Funds to Watch Weight Loss Drugs Market Size,

Information on state Medicaid coverage of GLP-1s for obesity comes from a January 2026 report from KFF, a nonpartisan research organization focused on health policy

Zelniker et al 27 performed a meta-analysis and found that SGLT-2 inhibitors protected the kidney better than GLP-1 receptor agonists did

I.YazdiZ

(For a fuller breakdown of compounded tirzepatide vs the brand-name versions like Mounjaro and Zepbound, see our compounded tirzepatide vs Mounjaro and Zepbound guide.) If you specifically want tirzepatide (the more effective dual GIP/GLP-1 receptor agonist) but wont inject yourself, SkinnyRx is currently your only path to that exact combination

At UC Davis Health, researchers are taking a holistic approach examining GLP-1 drugs across multiple systems, from gastrointestinal and cardiovascular physiology to musculoskeletal and neurocognitive function

You still need to confirm what is (and what is not) included in the package